Research Strategy

We directly fund and encourage high quality research and innovation in MSK health 

We can enable clinicians and scientists to support the millions of people suffering from poor bone, joint and muscle health.

Our 2024-27 research strategy places a heavy focus on research projects most capable of delivering benefits to patients and the healthcare system in a relatively short time-span, either by creating new MSK solutions (innovative products and services) or improving clinical practices and processes.

During the past decade we have invested £13.59m on research projects that expand knowledge, improve patient outcomes and pioneer new forms of diagnosis and treatment, including the application of AI and digital technologies.

We can enable clinicians and scientists to support the millions of people suffering from poor bone, joint and muscle health by:

• Focusing our investments on research projects most capable of delivering benefits to patients and the healthcare system in a relatively short time-span.
• Partnering with leading academic institutions, healthcare organisations, societies, charities (primarily as part of ARMA) and private companies.
• Supporting the overall research eco-system, especially at a time when clinical research faces significant challenges.
• Helping to accelerate the translation of research ideas into new
  products or services.
• Working with others to encourage the development of a more equal, diverse and inclusive research culture, and make the case for increased investment in MSK conditions.

According to our CEO, Dr Arash Angadji, ‘Our strategy aims to support MSK researchers throughout their careers. This includes helping the more entrepreneurially-minded researchers translate their ideas into new products and services.’